from Brown University and he has an M.B.A. in finance and international business from Columbia University Business School.
Nicholas Davies, Ph.D., is a partner in the pharmaceutical and life sciences practice at PricewaterhouseCoopers (PwC), responsible for pharmaceutical and research and development strategy. He has been a key figure in the pharmaceutical life sciences consulting and pharmaceutical industry for over 16 years and possesses extensive knowledge spanning research, development, commercial and marketing, and the external payer, access, and regulator environments. Prior to joining PwC, Dr. Davies was responsible for global research and development strategy at Pfizer and led a number of key research and development transformations, integrations, and mergers. As a former PwC management consultant and IBM business consulting research and development leader, he led and delivered complex engagements in major mergers and acquisitions, extensive restructuring and downsizing, research and development productivity projects, personalized medicine and diagnostics strategies, portfolio and decision making strategies, outsourcing, clinical research organization and partnering strategies, operational strategies in discovery and clinical development, enterprise risk management, Asia and emerging market strategies, out-and in-licensing, and commercial assessments of pipeline assets. He has also led research laboratories and departments at Novartis and AstraZeneca. Dr. Davies gained his Ph.D. in immunology and genetics at Cambridge University, UK.
Radoje Drmanac, Ph.D., is a co-founder of Complete Genomics and has served as chief scientific officer since July 2005. In 2001, Dr. Drmanac cofounded Callida Genomics, Inc., a DNA sequencing company, and served as Callida’s chief scientific officer from 2001 to 2004 and as its president since 2004. In 1994, Dr. Drmanac co-founded Hyseq, Inc., a DNA array technology company that became Hyseq Pharmaceuticals, Inc. and later merged with Variagenics, Inc. to become Nuvelo, Inc., and served as its senior vice president of research from 1994 to 1998 and as its chief scientific officer from 1998 to 2001. Prior to that, Dr. Drmanac served as a group leader at Argonne National Laboratory. Dr. Drmanac received a B.S., M.S., and Ph.D. in molecular biology from the University of Belgrade.
Deborah Dunsire, M.D., has been the president and chief executive officer of Millennium Pharmaceuticals Inc., since July 2005. In 2008 Millennium was acquired by Takeda Pharmaceuticals of Japan, becoming the global oncology center of excellence for Takeda under her leadership. Dr. Dunsire joined Millennium from her role as senior vice president and North American region head of the oncology business unit of Novartis. Prior to her move to the United States in 1994, Dr. Dunsire worked in the global headquarters